Clinical Trial Update: Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab in combination with pegylated interferon α-2b for indolent B-cell lymphoma is under investigation with status not stated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Lymphoma
• Lymphoma B-cell

Drugs mentioned

• Pegylated Interferon α-2b (pegylated interferon alfa-2b)
• Rituximab (rituximab)

Snippet

Sponsor: Huiqiang Huang | Conditions: Lymphoma, B-Cell | Phase 2 | Status: UNKNOWN